Krishnaswami Vijayaraghavan

Dr. Krishnaswami Vijayaraghavan

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan
Type 2 diabetes is associated with significant cardiovascular morbidity and mortality. Although low-density lipoprotein cholesterol levels may be normal in patients with type 2 diabetes, insulin resistance drives a number of changes in lipid metabolism and lipoprotein composition that render low-density lipoprotein cholesterol and other lipoproteins more pathogenic than species found in patients without type 2 diabetes. Dyslipidemia, which affects almost 50% of patients with type 2 diabetes, is a cardiovascular risk factor characterized by elevated triglyceride levels, low high-density lipoprotein cholesterol levels, and a preponderance of small, dense, low-density lipoprotein particles. Early, aggressive pharmacological management is advocated to reduce low-density lipoprotein cholesterol levels, regardless of baseline levels. A number of lipid-lowering agents, including statins, fibrates, niacin, and bile acid sequestrants, are available to target normalization of the entire lipid profile. Despite use of combination and high-dose lipid-lowering agents, many patients with type 2 diabetes do not achieve lipid targets. This review outlines the characteristics and prevalence of dyslipidemia in patients with type 2 diabetes and discusses strategies that may reduce the risk of cardiovascular disease in this population.

1 May 2021 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
Dinesh K. KalraDinesh K. Kalra
Dinesh K. Kalra
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan
GSGeeta Sikand
Geeta Sikand
NDNihar R. Desai
Nihar R. Desai
PJParag H. Joshi
Parag H. Joshi
ABAlan Brown
Alan Brown

1 February 2011 in Cardiology Clinics
Verified
Journal Article
Closed access
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan
PDPrakash Deedwania
Prakash Deedwania

25 March 2022 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
RPRaman Puri
Raman Puri
VMVimal Mehta
Vimal Mehta
PDP. Barton Duell
P. Barton Duell
SIS.S. Iyengar
S.S. Iyengar
JYJamal Yusuf
Jamal Yusuf
NWNathan D. Wong
Nathan D. Wong

15 January 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan
SBS. Baum
S. Baum
NDN. R. Desai
N. R. Desai
SVS. J. Voyce
S. J. Voyce
Introduction: Statins remain the first-line treatment for secondary prevention of cardiovascular (CV) events, with lowering of low-density lipoprotein cholesterol (LDL-C) being their therapeutic target. Although LDL-C reduction significantly lowers CV risk, residual risk persists, even in patients with well-controlled LDL-C; thus, statin add-on agents that target pathways other than LDL-C, such as the omega-3 fatty acid eicosapentaenoic acid, may help to further reduce persistent CV risk in patients with established CV disease.Methods: This narrative review examines the contemporary literature assessing intermediate- and long-term event rates in patients with established CV disease treated with statins.Results: CV event rates among patients treated with statins who have established CV disease, including coronary artery disease, cerebrovascular disease, or peripheral arterial disease, accumulate over time, with a cumulative incidence of CV events reaching up to approximately 40% over 10 years. Recurrent stroke occurs in up to 19% of patients seven years after a first cerebrovascular event. Repeat revascularization and CV-related death occurs in up to 38% and 33% of patients with peripheral artery disease after three years, respectively.Discussion: Additional treatment strategies, such as eicosapentaenoic acid, are needed to reduce persistent CV risk in patients with established CV disease treated with statins.

27 July 2024 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
FRFrederick Berro Rivera
Frederick Berro Rivera
EAEloise Arias-Aguirre
Eloise Arias-Aguirre
ZAZedrick Aguirre
Zedrick Aguirre
MYMc John C. Ybañez
Mc John C. Ybañez
JRJanos Marc M. Rubia
Janos Marc M. Rubia
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan